Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1490630

The Characteristics of Patients with Multiple Myeloma Surviving Over 10 Years

Provisionally accepted
Beihui Huang Beihui Huang Hongning Zhang Hongning Zhang Junru Liu Junru Liu Jingli Gu Jingli Gu Meilan Chen Meilan Chen Lifen Kuang Lifen Kuang Xiaozhe Li Xiaozhe Li Juan Li Juan Li *
  • Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

The final, formatted version of the article will be published soon.

    Objective: To explore the characteristics of patients with multiple myeloma (MM) who have achieved long-term survival of over 10 years in the context where novel agents and autologous stem cell transplantation (ASCT) serve as the primary therapeutic modalities.Methods: A retrospective analysis was conducted on 168 MM patients diagnosed and treated in our institution from January 2004 to January 2014. 44 patients with a survival period exceeding 10 years were categorized into the long-term survival group, while 124 patients with a survival period of less than 10 years were categorized into the non-long-term survival group.Results: Being younger than 57 years old (OR 3.364, 95% CI 1.214-9.320), having a neutrophil count of at least 3.66 * 10 9 /L (OR 3.122, 95% CI 1.093-8.918), absence of high-risk genetic abnormalities (OR 6.480, 95% CI 1.013-41.454), and receiving frontline ASCT (OR 4.564, 95% CI 1.127-18.486) were positively associated with a survival period exceeding 10 years in patients with MM. Achieving sustained minimal residual disease (MRD) negativity for at least 24 months is associated with long-term survival regardless of the presence of high-risk cytogenetic abnormalities.Being younger, having a neutrophil count above 3.66 * 10 9 /L, the absence of high-risk cytogenetic abnormalities, and receiving frontline ASCT are independent protective factors for transplant-eligible MM patients to survive more than 10 years. Achieving maintained MRD negativity status for over 24 months might be associated with long-term survival.

    Keywords: Multiple Myeloma, Long-term survival, prognostic factors, survival analysis, Minimal Residual Disease

    Received: 03 Sep 2024; Accepted: 05 Nov 2024.

    Copyright: © 2024 Huang, Zhang, Liu, Gu, Chen, Kuang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Juan Li, Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.